Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
18 hedge funds and large institutions have $3.02M invested in Petros Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
6% more funds holding
Funds holding: 17 → 18 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.01% less ownership
Funds ownership: 0.05% → 0.04% (-0.01%)
29% less capital invested
Capital invested by funds: $4.23M → $3.02M (-$1.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$176K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60K |
| 3 |
VF
Virtu Financial
New York
|
+$45.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$30.4K |
| 5 |
NFSG
Newbridge Financial Services Group
Boca Raton,
Florida
|
+$4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$417K |
| 2 |
NP
NorthRock Partners
Minneapolis,
Minnesota
|
-$378K |
| 3 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$161K |
| 4 |
FIA
FNY Investment Advisers
New York
|
-$73K |
| 5 |
SC
Shay Capital
New York
|
-$57.6K |
PTPI Hedge Fund Activity: Q2 2021 in Review
18 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q2 2021, worth a combined $3.02M — down 29% from $4.23M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PTPI positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was CM Management, adding an estimated $176K. The largest seller was Renaissance Technologies, cutting an estimated $417K.
- 18 institutional investors held Petros Pharmaceuticals (PTPI) as of Q2 2021, up from 17 in Q1 2021.
- Funds reported $3.02M of Petros Pharmaceuticals stock for Q2 2021, down 29% quarter-over-quarter.
- 5 funds opened new Petros Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of +1 holder.
- The largest Petros Pharmaceuticals buyer in Q2 2021 was CM Management, an estimated $176K added.
- The largest Petros Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $417K sold.
Based on aggregated 13F filings for Q2 2021.